Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma

Published:2022-09 Issue:3 Volume:77 Page:683-694
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Chuah Samuel^ORCID,Lee Joycelyn^ORCID,Song Yuan^ORCID,Kim Hyung-Don,Wasser Martin^ORCID,Kaya Neslihan A.,Bang Kyunghye,Lee Yong Joon,Jeon Seung Hyuck^ORCID,Suthen Sheena^ORCID,A’Azman Shamirah,Gien Gerald,Lim Chun Jye^ORCID,Chua Camillus,Hazirah Sharifah Nur,Lee Hong Kai,Lim Jia Qi,Lim Tony K.H.,Yeong Joe,Chen Jinmiao,Shin Eui-Cheol^ORCID,Albani Salvatore,Zhai Weiwei,Yoo Changhoon,Liu Haiyan,Choo Su Pin^ORCID,Tai David,Chew Valerie^ORCID

Funder

National Medical Research Council

Publisher

Elsevier BV

Subject

Hepatology

Reference38 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Nivolumab vs. sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial;Yau;Lancet Oncol,2022

3. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial;Finn;J Clin Oncol,2020

4. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040;Yau;J Clin Oncol,2019

5. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The implications of the TNFα‐TNFR2 immune checkpoint signaling pathway in cancer treatment: From immunoregulation to angiogenesis;International Journal of Cancer;2024-08-14

2. Preoperative MRI features for predicting response to postoperative adjuvant anti-PD-1 therapy in hepatocellular carcinoma;2024-08-11

3. Memory inflation: Beyond the acute phase of viral infection;Cell Proliferation;2024-07-11

4. Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation;Journal of Hepatology;2024-06

5. Recent advances in hepatocellular carcinoma-targeted nanoparticles;Biomedical Materials;2024-05-23